80% of Empiric Therapy is unnecessary. The high negative predictive value of β-D-Glucan cuts this over-use dramatically.
Intravenous antifungal agents are commonly prescribed empirically for patients at risk of invasive fungal infections. Yet around 80% of empirically prescribed antifungal treatments are shown to be unnecessary with no evidence of Invasive Fungal Infection. The high negative predictive value of β-D-Glucan cuts this over-use dramatically..
Would you like a precis of key publications? Use the contact form below
These are from posters presented at a meeting in Aberdeen in October 2021 relevant to rapid fungal diagnostics & antifungal stewardship.
P356 - A retrospective review of the AFS at Leicester.
Absolute antifungal expenditure showed an annual decrease of £320,600
P222 - A multi-site evaluation of antifungal use- implications for AFS. ''β-D-glucan utilization is greatest when turn-around-time is shortest''
P062 - Introduction of β-D-glucan testing.
Based on bringing 256 tests in-house there was a saving of £75,000 in therapy.
Would you like abstracts of these presentations? There are more - use the contact form below.
Minimising laboratory turnaround times is key to unlocking the potential of β-D-Glucan. Patient to result in under 2 hours is now possible.
FACIS, Fully Automatic Chemiluminescence Immunoassay System, has the key attributes of being simple and economical to use making a 24/7 service for β-D-Glucan/Galactomannan testing a real possibility.
If you would like any of the following,
DOCUMENTS Product Information, Comparison with competitors, Evaluations, Certifications.
Make use of the contact form below .